The CCL5/CCR5 axis promotes metastasis in basal breast cancer

OncoImmunology

Volumn 2, Issue 4, 2013, Pages

  Velasco Velázquez, Marco ^a   Pestell, Richard G ^b,c  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Basal breast cancer; Ccl5; Ccr5; Maraviroc; Metastasis; Vicriviroc

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; MARAVIROC; RANTES; VICRIVIROC;

ARTICLE; BIOLUMINESCENCE; BREAST CANCER; CANCER CELL CULTURE; CANCER SURVIVAL; CELL PROLIFERATION; HISTOPATHOLOGY; HUMAN; LUNG METASTASIS; METASTASIS; METASTASIS POTENTIAL; NONHUMAN; PHENOTYPE; RISK FACTOR; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR VOLUME;

EID: 84886944330     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23659     Document Type: Article

References (10)

1. Velasco-Velázquez M, Jiao X, De La Fuente M, Pestell TG, Ertel A, Lisanti MP, et al. CCR5 antagonist blocks metastasis of basal breast cancer cells. Cancer Res 2012; 72:3839-50; PMID:22637726; http://dx.doi.org/10.1158/0008-5472.CAN-11-3917
2. Ertel A, Dean JL, Rui H, Liu C, Witkiewicz AK, Knudsen KE, et al. RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response. Cell Cycle 2010; 9:4153-63; PMID:20948315; http://dx.doi.org/10.4161/cc.9.20.13454
3. Meyers MO, Klauber-Demore N, Ollila DW, Amos KD, Moore DT, Drobish AA, et al. Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. Ann Surg Oncol 2011; 18:2851-7; PMID:21442348; http://dx.doi.org/10.1245/s10434-011-1665-8
4. Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol 2010; 28:3271-7; PMID:20498394; http://dx.doi.org/10.1200/JCO.2009.25.9820
5. Wilkin TJ, Su Z, Krambrink A, Long J, Greaves W, Gross R, et al. Three-year safety and efficacy of vicriviroc, a CCR5 antagonist, in HIV-1-infected treatmentexperienced patients. J Acquir Immune Defic Syndr 2010; 54:470-6; PMID:20672447; http://dx.doi.org/10.1097/QAI.0b013e3181e2cba0
6. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, Macartney M, et al. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 2005; 49:4721-32; PMID:16251317; http://dx.doi.org/10.1128/AAC.49.11.4721-4732.2005
7. Mañes S, Mira E, Colomer R, Montero S, Real LM, Gómez-Moutón C, et al. CCR5 expression influences the progression of human breast cancer in a p53-dependent manner. J Exp Med 2003; 198:1381-9; PMID:14597737; http://dx.doi.org/10.1084/jem.20030580
8. Murooka TT, Rahbar R, Fish EN. CCL5 promotes proliferation of MCF-7 cells through mTOR-dependent mRNA translation. Biochem Biophys Res Commun 2009; 387:381-6; PMID:19607806; http://dx.doi.org/10.1016/j.bbrc.2009.07.035
9. Vaday GG, Peehl DM, Kadam PA, Lawrence DM. Expression of CCL5 (RANTES) and CCR5 in prostate cancer. Prostate 2006; 66:124-34; PMID:16161154; http://dx.doi.org/10.1002/pros.20306
10. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007; 449:557-63; PMID:17914389; http://dx.doi.org/10.1038/nature06188